We expect investors to focus on the sales performance of ChromaDex Corp.'s (CDXC) marketed product, Niagen, and updates on the pipeline when it reports third-quarter 2024 results on Oct. 31, after market close. The Zacks Consensus Estimate for the to-be-reported quarter's revenues is pegged at $23.70 million, while the same for earnings is pinned at 1 cent per share. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. Let's see how things might have shaped up for the quarter to be repo ...